Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
21-Hydroxylase Deficiency: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
21-Hydroxylase Deficiency: 3 US clinical trials tracked, none currently recruiting.
21-Hydroxylase Deficiency is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Maria I. New, running 1 of these trials.
Enrollment posture brief
Registry condition 21-hydroxylase-deficiency
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
21-Hydroxylase Deficiency has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for 21-Hydroxylase Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
21-Hydroxylase Deficiency is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency
Maria I. New
NCT00542841
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Neurocrine UK Limited
NCT00519818
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT01495910
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on 21-Hydroxylase Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on 21-Hydroxylase Deficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this 21-Hydroxylase Deficiency page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No 21-Hydroxylase Deficiency trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Maria I. New sponsors the most 21-Hydroxylase Deficiency trials on record, review their full trial history before evaluating a specific study. See Maria I. New's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This 21-Hydroxylase Deficiency condition card totals 3 registered trials; most-linked intervention Hydrocortisone withdrawal; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.